Rigel Pharmaceuticals Inc
F:RI2A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Rigel Pharmaceuticals Inc
F:RI2A
|
US |
|
E
|
Edwards Lifesciences Corp
F:EWL
|
US |
|
V
|
Verisk Analytics Inc
XBER:VA7A
|
US |
|
S
|
Sino Land Co Ltd
SWB:SNO
|
HK |
Wall St Price Targets
RI2A Price Targets Summary
Rigel Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for RI2A is 16.46 EUR with a low forecast of 11.64 EUR and a high forecast of 25.79 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RI2A's stock price target?
Price Target
16.46
EUR
According to Wall Street analysts, the average 1-year price target for RI2A is 16.46 EUR with a low forecast of 11.64 EUR and a high forecast of 25.79 EUR.
What is the Revenue forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Revenue has been 45%. The projected CAGR for the next 3 years is 7%.
What is the Gross Profit forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
13%
The compound annual growth rate for Gross Profit over the next 3 years is 13%.
What is the Operating Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-2%
The compound annual growth rate for Operating Income over the next 3 years is -2%.
What is the Pre-Tax Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-6%
The compound annual growth rate for Pre-Tax Income over the next 3 years is -6%.
What is the Net Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-40%
The compound annual growth rate for Net Income over the next 3 years is -40%.
